Modella AI, a company specialising in generative and agentic artificial intelligence for biomedicine, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its advanced AI-driven diagnostic tool, PathChat DX.
This recognition highlights the potential of the technology to improve pathology workflows and enhance patient care.
The FDA grants Breakthrough Device Designation to medical innovations that demonstrate significant benefits over current standards of care, particularly those addressing unmet clinical needs. PathChat DX is an extension of the PathChat model, which was recently featured in Nature.
The tool combines generative AI with multimodal analysis to support pathologists in diagnosing complex cases more accurately and efficiently.
It utilises pathology foundation models trained on extensive histology image and image-text datasets, along with a custom-trained multimodal large language model (MLLM) for analysing high-resolution pathology images and clinical data.
With this designation, Modella AI will benefit from a streamlined review process and closer collaboration with the FDA, accelerating the path to market for PathChat DX.
The recognition also reflects the FDA’s confidence in the tool’s ability to address key challenges in pathology, such as diagnostic variability and increasing case volumes.
The introduction of PathChat DX is expected to enhance diagnostic precision and potentially reduce the time required for diagnosis.
By improving workflow efficiency, the technology aims to support pathologists in managing rising workloads and reducing professional burnout, contributing to better patient outcomes.
